Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1287-1294

  Von Leoprechting, Achim ^a   Van Der Bruggen, Pierre ^b   Pahl, Heike L ^a   Aruffo, Alejandro ^c   Simon, Jan C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD40; APOPTOSIS; CELL DIVISION; CYTOKINES; HUMANS; IN SITU HYBRIDIZATION; LYMPHOCYTE SUBSETS; MELANOMA; NF-KAPPA B; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0033559616     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Stout, R. D., and Suttles, J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol. Today, 17: 487-492, 1996.
2. Grewal, I. S., and Flavell, R. A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol., 16: 111-135, 1998.
3. Young, L. S., Eliopoulos, A. G., Gallagher, N. J., and Dawson, C. W. CD40 and epithelial cells: across the great divide. Immunol. Today, 19: 502-506, 1998.
4. Sad, S., Krishnan, L., Bleackley, R. C., Kägi, D., Hengartner, H., and Mosmann, T. R. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity. Eur. J. Immunol., 27: 914-922, 1997.
5. Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R., Miller, J. F. A. P., and Heath, W. R. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature (Lond.), 393: 478-480, 1998.
6. Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., and Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (Lond.), 393: 480-483, 1998.
7. Mackey, M. F., Barth, R. J., Jr., and Noelle, R. J. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukocyte Biol., 63: 418-428, 1998.
8. Borrow, P., Tishon, A., Lee, S., Xu, J., Grewal, J. S., Oldstone, M. B., and Flavell, R. A. CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CDS+ CTL response. J. Exp. Med., 183: 2129-2142, 1996.
9. Mackey, M. F., Gunn, J. R., Ting, P. P., Kikutani, H., Dranoff, G., Noelle, R. J., and Barth, R. J., Jr. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand. CD154. Cancer Res., 57: 2569-2574, 1997.
10. Bergamo, A., Bataille, R., and Pellat-Deceunynck, C. CD40 and CD95 induce cell death in the human myeloma cell line XG2. Br. J. Haematol., 97: 652-655, 1997.
11. Hess, S., and Engelmann, H. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. 183: 159-167, 1996.
12. Rohbins, P. F., and Kawakami, Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol., X: 628-636, 1996.
13. Herin, M., Lemoine, C., Weynants, P., Vessiere, F., Van Pel, A., Knuth, A., Devos, R., and Boon, T. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int. J. Cancer, 39: 390-396, 1987.
14. Van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
15. Mattei, S., Colombo, M. P., Melani, C., Silvani, A., Parmiani, G., and Herlyn, M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer, 56: 853-857, 1994.
16. May, M. J., and Ghosch, S. Signal transduction through NF-κB. Immunol. Today. 19: 80-89, 1998.
17. van den Oord, J. J., Maes, A., Stas, M., Nuyts, J., Battocchio, S., Kasran, A., Garmyn, M., De Wever, I., and De Wolf-Peeters, C. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol., 149: 1953-1961, 1996.
18. Thomas, W. D., Smith, M. J., Si, Z., and Hersey, P. Expression of the costimulatory molecule CD40 on melanoma cells. Int. J. Cancer, 68: 795-801, 1996.
19. Hollenbaugh, D., Mischel-Petty, N., Edwards, C. P., Simon, J. C., Dcnfeld, R. W., Kiener, P. A., and Aruffo, A. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med., 182: 33-40, 1995.
20. Salter, R. D., Howell, D. N., and Cresswell, P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics, 21: 235-246, 1985.
21. van den Eynde, B. Hainaut, P., Herin, M., Knuth, A., Lemone, C., Weynants, P., van den Bruggen, P., Fauchet, R., and Boon, T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer, 44: 634-640, 1989.
22. Pahl, H. L., Sester, M., Burgert, H., and Baeuerle, P. A. Activation of Transcription factor NF-κB by the Adenovirus E3/19K protein requires its ER retention. J. Cell Biol., 132: 511-522, 1996.
23. van Muijen, O. N., Danen, E. H., Veerkamp, J. H., Ruiter, D. J., Lesley, J., and van den Heuvel, L. P. Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. Int. J. Cancer, 61: 241-248, 1995.
24. Stamenkovic, I., Clark, E. A., and Seed, B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J., 8: 1403-1410, 1989.
25. Colombo, M. P., Maccalli, C., Mattei, S., Melani, C., Radrizzani, M., and Parmiani, G. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res., 2: 181-189, 1992.
26. Berberich, I., Shu, G. L., and Clark, E. A. Cross-linking CD40 on B cells rapidly activates nuclear factor-κB. J. Immunol., 153: 4357-4366, 1994.
27. Hess, S., Rensing-Ehl, A., Schwabe, R., Bufler, P., and Engelmann, H. CD40 function in non-hematopoietic cells. Nuclear factor κB mobilization and induction of IL-6 production. J. Immunol., 155: 4588-4595, 1995.
28. Henkel, T., Machleidt, T., Alkalay, I., Krönke, M., Ben, N. Y., and Baeuerle, P. A. Rapid proteolytic degradation of IκBα induced by stimulation of cell with phorbol ester, cytokines and liposaccharides is a necessary step in the activation of transcription factor NF-κB. Nature (Lond.), 365: 182-184, 1993.
29. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
30. Goldstein, M. D., and Watts, T. H. Identification of distinct domains in CD40 involved in B7-I induction or growth inhibition. J. Immunol., 157: 2837-2843, 1996.
31. Funakoshi, S., Longo, D. L., Beckwith, M., Conley, D. K., Tsarfaty, G., Tsarfaty, I., Armitage, R. J., Fanslow, W. C., Spriggs, M. K., and Murphy, W. J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood, 83: 2787-2794, 1994.
32. Schwartz, L. M., and Osborne, B. A. Programmed cell death, apoptosis and killer genes. Immunol. Today, 14: 582-590, 1993.
33. Armstrong, C. A., Botella, R., Galloway, T. H., Murray, N., Kramp, J. M., Song, I. S., and Ansel, J. C. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res., 56: 2191-2198, 1996.
34. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
35. Armstrong, C. A., Murraym N., Kennedy, M., Koppula, S. V., Tara, D., and Ansel, J. C. Melanoma-derived interleukin 6 inhibits in vivo melanoma growth. J. Invest. Dermatol., 102: 278-284, 1994.
36. Baggiolini, M., and Clark-Lewis, I. lnterleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett., 307: 97-101, 1992.
37. Beutler, B., and Cerami, A. The biology of cachectin/TNF-α. Annu. Rev. Immunol., 7: 625-655, 1989.
38. Garbe, C., and Krasagakis, K. Effects of interferons and cytokines on melanoma cells. J. Invest Dermatol., 100: 239-244, 1993.
39. Rivoltini, L., Barracchini, K. C., Viggiano, V., Kawakami, Y., Smith, A., Mixon, A., Restifo, N. P., Topalain, S. L., Rosenberg, S. A., and Marincola, F. M. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cylotoxic T lymphocytes. Cancer Res., 55: 3149-3157, 1995.
40. Cayabyab, M., Phillips, J. H., and Lanier, L. L. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J. Immunol., 152: 1523-1531, 1994.
41. Hermann, P., Van-Kooten, C., Gaillard, C., Banchereau, J., and Blanchard, D. CD40 ligand-positive CDS+ T cell clones allow B cell growth and differentiation. Eur. J. Immunol., 25: 2972-2977, 1995.
42. Becker, J. C., Dummer, R., Hartmann, A. A., Burg, G., and Schmidt, R. E. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-γ and tumor necrosis factor-α. J. Immunol., 147: 4398-4401, 1991.
43. Rünger, T. M., Klein, C. E., Becker, J. C., and Bröcker, E. B. The role of genetic instability, adhesion, cell motility, and immune escape mechanisms in melanoma progression. Curr. Opin. Oncol., 6: 188-196, 1994.
44. Tartaglia, L. A., Ayres, T. M., Wong, G. H., and Goeddelm D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 74: 845-853, 1993.
45. Itoh, N., and Nagata, S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J. Biol. Chem., 268: 10932-10937, 1993.
46. Bohm, W., Thoma, S., Leithauser, F., Moller, P., Schirmbeck, R., and Reimann, J. T-cell mediated. IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161: 897-908, 1998.